Literature DB >> 21875163

Early assessment of medical technologies to inform product development and market access: a review of methods and applications.

Maarten J Ijzerman1, Lotte M G Steuten.   

Abstract

Worldwide, billions of dollars are invested in medical product development and there is an increasing pressure to maximize the revenues of these investments. That is, governments need to be informed about the benefits of spending public resources, companies need more information to manage their product development portfolios and even universities may need to direct their research programmes in order to maximize societal benefits. Assuming that all medical products need to be adopted by the heavily regulated healthcare market at one point in time, it is worthwhile to look at the logic behind healthcare decision making, specifically, decisions on the coverage of medical products and decisions on the use of these products under competing and uncertain conditions. With the growing tension between leveraging economic growth through R&D spending on the one hand and stricter control of healthcare budgets on the other, several attempts have been made to apply the health technology assessment (HTA) methodology to earlier stages of technology development and implementation. For instance, horizon scanning was introduced to systematically assess emerging technologies in order to inform health policy. Others have introduced iterative economic evaluation, e.g. economic evaluations in earlier stages of clinical research. However, most of these methods are primarily intended to support governments in making decisions regarding potentially expensive new medical products. They do not really inform biomedical product developers on the probability of return on investment, nor do they inform about the market needs and specific requirements of technologies in development. It is precisely this aspect that increasingly receives attention, i.e. is it possible to use HTA tools and methods to inform biomedical product development and to anticipate further development and market access. Several methods have been used in previous decades, but have never been compiled in a comprehensive review. The main objective of this article was to provide an overview of previous work and methods in the field of early HTA, and to put these approaches in perspective through a conceptual framework introduced in this paper. A particular goal of the review was to familiarize decision makers with available techniques that can be employed in early-stage decision making, and to identify opportunities for further methodological growth in this emerging field of HTA.

Mesh:

Year:  2011        PMID: 21875163     DOI: 10.2165/11593380-000000000-00000

Source DB:  PubMed          Journal:  Appl Health Econ Health Policy        ISSN: 1175-5652            Impact factor:   2.561


  42 in total

1.  Circulating Tumour DNA as a Potential Cost-Effective Biomarker to Reduce Adjuvant Chemotherapy Overtreatment in Stage II Colorectal Cancer.

Authors:  Yat Hang To; Koen Degeling; Suzanne Kosmider; Rachel Wong; Margaret Lee; Catherine Dunn; Grace Gard; Azim Jalali; Vanessa Wong; Maarten IJzerman; Peter Gibbs; Jeanne Tie
Journal:  Pharmacoeconomics       Date:  2021-06-05       Impact factor: 4.981

2.  A call for pharmacogenovigilance and rapid falsification in the age of big data: why not first road test your biomarker?

Authors:  Semra Şardaş; Laszlo Endrenyi; Ulvi K Gürsoy; Mara Hutz; Biaoyang Lin; George P Patrinos; Lotte M G Steuten; Wei Wang; Louise Warnich; Vural Özdemir
Journal:  OMICS       Date:  2014-10-29

Review 3.  Improving Evaluation to Address the Unintended Consequences of Health Information Technology:. a Position Paper from the Working Group on Technology Assessment & Quality Development.

Authors:  F Magrabi; E Ammenwerth; H Hyppönen; N de Keizer; P Nykänen; M Rigby; P Scott; J Talmon; A Georgiou
Journal:  Yearb Med Inform       Date:  2016-11-10

4.  Patients' preferences for anti-osteoporosis drug treatment: a cross-European discrete choice experiment.

Authors:  Mickaël Hiligsmann; Benedict G Dellaert; Carmen D Dirksen; Verity Watson; Sandrine Bours; Stefan Goemaere; Jean-Yves Reginster; Christian Roux; Bernie McGowan; Carmel Silke; Bryan Whelan; Adolfo Diez-Perez; Elisa Torres; Georgios Papadakis; Rene Rizzoli; Cyrus Cooper; Gill Pearson; Annelies Boonen
Journal:  Rheumatology (Oxford)       Date:  2017-07-01       Impact factor: 7.580

Review 5.  Cost effectiveness of first-line oral antiviral therapies for chronic hepatitis B : a systematic review.

Authors:  María Buti; Itziar Oyagüez; Virginia Lozano; Miguel A Casado
Journal:  Pharmacoeconomics       Date:  2013-01       Impact factor: 4.981

6.  Multi-Dimensional Impact of the Public-Private Center for Translational Molecular Medicine (CTMM) in the Netherlands: Understanding New 21(st) Century Institutional Designs to Support Innovation-in-Society.

Authors:  Lotte M Steuten
Journal:  OMICS       Date:  2016-05

7.  Early economic evaluation of emerging health technologies: protocol of a systematic review.

Authors:  Ba' Pham; Hong Anh Thi Tu; Dolly Han; Petros Pechlivanoglou; Fiona Miller; Valeria Rac; Warren Chin; Andrea C Tricco; Mike Paulden; Joanna Bielecki; Murray Krahn
Journal:  Syst Rev       Date:  2014-07-23

8.  Outcome Priorities for Older Persons With Sarcopenia.

Authors:  Mickael Hiligsmann; Charlotte Beaudart; Olivier Bruyère; Emmanuel Biver; Jürgen Bauer; Alfonso J Cruz-Jentoft; Antonella Gesmundo; Sabine Goisser; Francesco Landi; Médéa Locquet; Stefania Maggi; Rene Rizzoli; Yves Rolland; Nieves Vaquero; Cyrus Cooper; Jean-Yves Reginster
Journal:  J Am Med Dir Assoc       Date:  2019-10-28       Impact factor: 4.669

9.  Reporting Guidelines for the Use of Expert Judgement in Model-Based Economic Evaluations.

Authors:  Cynthia P Iglesias; Alexander Thompson; Wolf H Rogowski; Katherine Payne
Journal:  Pharmacoeconomics       Date:  2016-11       Impact factor: 4.981

10.  Biomarkers for Early Detection of Colorectal Cancer: The Early Detection Research Network, a Framework for Clinical Translation.

Authors:  Robert S Bresalier; William M Grady; Sanford D Markowitz; Hans Jørgen Nielsen; Surinder K Batra; Paul D Lampe
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2020-04-16       Impact factor: 4.254

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.